Pharmaceutical companies have agreed to negotiate prices for 10 drugs.
First-line treatment guided by biomarker testing results improves survival in patients with advanced non-small cell lung cancer, a study suggests.
Researchers have identified first-line treatment regimens that appear to be associated with the best outcomes in advanced, unresectable ESCC.
New research suggests that, in the United States, the use of palliative care for metastatic breast cancer varies by race.
Caregivers of adult cancer patients are not typically screened for distress, a new study suggests.
The FDA has accepted for priority review the biologics license application for odronextamab to treat adults with relapsed/refractory FL or DLBCL whose disease has progressed after at least 2 prior systemic therapies.
This year’s Nobel Prize in physiology or medicine has been awarded to 2 scientists who laid the groundwork for the mRNA research that made COVID-19 vaccines possible.
Breast Cancer Awareness Month promotes education on testing and detecting breast cancer early. This means understanding breast cancer symptoms, and how the disease progresses by stage. Does the staging of breast cancer affect symptoms?
Patients who experience high levels of discrimination are more willing to participate in clinical trials, a survey suggests.
Excellent adherence to hormone therapy after surgery for DCIS can improve outcomes, when compared to good or low adherence, researchers say.
Prophylactic radiation for asymptomatic bone metastases can improve outcomes in patients with solid tumor malignancies, a phase 2 study suggests.
A dendritic cell vaccine, when given before and after stem cell transplant, may improve responses in patients with multiple myeloma, researchers say.
The FDA has become “increasingly concerned” that some laboratory-developed tests may not provide accurate results.
Some people have been denied insurance coverage while seeking COVID-19 vaccinations at pharmacies.
AI has been used in oncology for years, but recent studies suggest AI could have many additional applications in cancer care.
Researchers say they have identified adverse events that are more likely to occur in cancer patients receiving antibody-drug conjugates.
Local therapy improves overall survival in patients with clinically lymph node-positive prostate cancer, a meta-analysis suggests.
There was a decrease in new cancer diagnoses, relative to expected numbers, between March 2020 and May 2020, according to a report.
Bariatric surgery is associated with a lower risk of hematologic cancer in women, a study suggests.
Diabetes increases the likelihood of upstaging in patients with clinical T1 RCC undergoing partial or radical nephrectomy, a study suggests.
Gilead has discontinued the ENHANCE-2 study, which was designed to evaluate magrolimab in AML patients with TP53 mutations.
For the first time since 2019, congressional gridlock is poised to temporarily shut down big parts of the federal government, including many health programs.
In a recent survey, 70% of cancer patients said they use complementary or alternative medicine as part of their cancer care.
Researchers say they have identified which patients with rhabdomyosarcoma are most likely to benefit from radiotherapy.
Seeking the right treatment for the right patient at the right time By PRI Healthcare Solutions At the beginning of 2023, the American Cancer Society annual report on prostate cancer took a page from A Tale of Two Cities: It was the best of times, it was the worst of times … it was the…
Good oral health is associated with improved survival in patients with head and neck cancer, a study suggests.
The FDA has approved bosulif (bosutinib) for patients aged 1 year or older with chronic phase Ph+ CML.
More than half of US adults surveyed said they “definitely” or “probably” won’t be vaccinated with one of the updated COVID-19 vaccines.
Researchers are evaluating the effects of adding atezolizumab to adjuvant treatment with trastuzumab emtansine in patients with HER2-positive breast cancer.
Researchers have found several differences in cancer rates between members of the US military and the general US population.
Researchers say they have identified genes that should be considered for gene panel testing in prostate cancer.
Patients with metastatic breast cancer who receive alpelisib in clinical practice have higher rates of hyperglycemia than patients who receive the drug in clinical trials, a new study suggests.
Combining neoadjuvant durvalumab with other agents improves response rates in patients with resectable non-small cell lung cancer.
Higher exposure to PFAS, phenols, and parabens is associated with previous cancer diagnosis in women but not men, a study suggests.
A Pfizer plant that makes drugs and hospital supplies has restarted production after a 10-week shutdown.
Researchers are conducting a phase 3 trial to compare Dato-DXd, with or without durvalumab, to investigator’s choice of treatment in patients with TNBC.
Privately-insured cancer patients living in states with restrictive telehealth policies were less likely to use telehealth in 2020 and 2021, a study showed.
Surgery to remove the primary tumor does not prolong overall survival in most patients with de novo metastatic breast cancer, a meta-analysis suggests.
Lymphoma patients who receive high-dose chemotherapy and autologous HSCT have an increased risk of second primary malignancies, data suggest.
Investigators tested a less aggressive chemoradiation protocol in patients with MIBC who were unfit for surgery due to age or comorbidities.
Comparing Medicare Part D plans can reduce financial toxicity associated with the use of oral androgen inhibitors in patients with advanced prostate cancer, a study suggests.
The use of aromatherapy at night improved mean scores of well-being in patients with cancer in a hospital setting.
Breast cancer patients without axillary lymph node involvement who have tumors no larger than 2 cm can safely forgo axillary surgery, a phase 3 trial suggests.
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
Using next-generation sequencing to guide treatment is feasible in patients with platinum-refractory head and neck cancer, according to researchers.
Female survivors of childhood cancer have a higher risk of subsequent breast cancer if they received doxorubicin, a study suggests.
As currently defined, biochemical recurrence after surgery or radiation is not a reliable predictor of the risk of death from prostate cancer, investigators say.
About 500,000 children and families have had their Medicaid reinstated after losing it because of a systems issue.
Online misinformation is harming cancer patients. YouTube has been part of the problem, but a new policy might change that.
First-line treatment with dabrafenib and trametinib can improve outcomes, when compared to standard chemotherapy, in children with
BRAF V600-mutated low-grade glioma, a phase 2 trial suggests.
The cancer vaccine OSE2101 improved survival in patients with HLA-A2+, advanced NSCLC and secondary resistance to ICIs in a phase 3 trial.
Prostate cancer patients treated with radiotherapy have a higher risk of developing and dying from bladder cancer or lung cancer than patients treated with radical prostatectomy alone, a study suggests.
Patients with CML have a higher risk of albuminuria if they receive dasatinib rather than other TKIs, a study suggests.
The FDA has granted fast track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.
The government will pay for about 200 million at-home COVID-19 tests to replenish the country’s stockpile.
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Researchers say they have detected breast cancer in ctDNA from breast milk, and breast milk may allow for earlier cancer detection than plasma.
Surveillance plays a major role in the management of men with cancer clinically confined to the testis.
Local testosterone delivery to the prostate bed might be a better marker of post-prostatectomy outcomes than serum testosterone in some men.
Pembrolizumab plus chemoradiotherapy is under priority review for newly diagnosed, high-risk, locally advanced cervical cancer.
A new study suggests that electronic health records could be better tailored to meet the specific needs of oncologists.
Researchers say they have quantified the global burden of lip and oral cavity cancers as well as other pharyngeal cancers.
Researchers have validated previously identified prognostic factors for pleural mesothelioma and identified “room for improvement” when predicting overall survival in this patient population.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
The FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.
The FDA has accepted for priority review the supplemental new drug application for belzutifan to treat adults with advanced renal cell carcinoma who previously received immune checkpoint and anti-angiogenic therapies.
Mississippi had the nation’s second-highest age-adjusted cervical cancer mortality rate from 2016 through 2020.
Long-term historical exposure to air pollution is associated with an increased risk of breast cancer, a new study suggests.
Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.
Data suggest that many patients with HER2+, metastatic colorectal cancer do not receive HER2-targeted therapy as recommended by NCCN guidelines.
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Diagnoses of in situ and invasive melanoma were stable from 2018 to 2019 but decreased from 2019 to 2020, researchers found.
Cancer deaths increased during the first 2 years of the COVID-19 pandemic in the United States, a population-based study suggests.
Taking adjuvant endocrine therapy for 7 to 8 years is likely sufficient for maximal disease-free survival benefits among most postmenopausal women with HR+ breast cancer, according to researchers.
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
Adding atezolizumab to bevacizumab and platinum-based chemotherapy did not improve PFS in recurrent, platinum-sensitive ovarian cancer.
Adding nivolumab to treatment with SABR improved the 4-year event-free survival rate in a phase 2 trial of patients with NSCLC.
Temozolomide is the second drug to receive a labeling update under Project Renewal.
When did Breast Cancer Awareness Month first begin, and what impact has it had on awareness and research in the years since?
Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
Researchers are evaluating whether a breath test can detect malignant pleural mesothelioma in patients with asbestos exposure, and early results suggest it may be possible.
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Tepotinib plus osimertinib has demonstrated efficacy in advanced,
EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.
Lowering medication costs can improve adherence to adjuvant endocrine therapy in breast cancer survivors, an analysis suggests.
Experts have recommended that, for patients with cancer-related pain who are using nonmedical stimulants, opioids should be continued, monitoring should be increased, and tapering should be avoided.
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
US patients with lung cancer have a higher burden of death from COVID-19 than the general population, and this has been the case since the omicron variant became dominant, data suggest.
Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.
A genetic testing station can increase uptake and improve the efficiency of genetic testing for patients with ovarian cancer, a study suggests.
Perioperative durvalumab does not adversely impact surgical outcomes in patients with resectable non-small cell lung cancer, results from the AEGEAN trial suggest.
Adding nimotuzumab to treatment with gemcitabine improves survival outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.
The CDC is recommending wide use of the updated mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna.
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC.
Adagrasib has shown durable clinical activity in patients with advanced
KRAS G12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
Patritumab deruxtecan (HER3-DXd) is effective in patients with previously treated,
EGFR-mutant NSCLC, a phase 2 study suggests.
Chemotherapy alone may produce better outcomes than surgery plus chemotherapy in patients with mesothelioma, the MARS 2 trial suggests.
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with
EGFR-mutant, advanced NSCLC, phase 3 data suggest.
Incidence rates of lung cancer subtypes vary across global regions, data suggest.